Diamyd Medical has entered into a collaboration agreement with DiaUnion, to identify participants for the DiaPrecise trial, an open-label trial evaluating the safety, feasibility and immune response of intralymphatic injections of Diamyd®? in children at risk of developing type 1 diabetes who also carry the HLA DR3-DQ2 genotype. The DiaPrecise trial has been initiated and is ongoing at the Department of Clinical Sciences at Lund University, Malmo, with Markus Lundgren M.D., PhD, as the Principal Investigator.

DiaPrecise is the first precision prevention trial with Diamyd®?, and is conducted under the ASSET program (AI for the Sustainable Prevention of Autoimmunity in Society, funded by the Swedish Innovation Agency VINNOVA. DiaPrecise is a consortium coordinated by the Medicon Valley Alliance involving also the Steno Diabetes Center Copenhagen and Lund University, Malmo, establishing a screening program to identify individuals positive for diabetes autoantibodies, and there at high risk for the disease. About DiaPrecise - Precision Prevention of Type 1 Diabetes: DiaPrecise is an open-label clinical trial where Diamyd®?

(GAD-alum) is given directly into a lymph node in 10 to 16 children aged 8 to 18 years who are at high risk of being diagnosed with clinical Type 1 Diabetes (so called Stage 1 or Stage 2 Type 1 Diabetes), and who also carry the genetically defined haplotype HLA DR3-D Q2, associated with clinical response to Diamyd®?. The aim of the trial is to evaluate the safety and feasibility of two or three intralymphatic injections with Diamyd®? as well as the effect on the immune system and clinical parameters including endogenous insulin production and blood glucose control.

The Principal Investigator of DiaPrecise is Dr. Markus Lundgren, Researcher at the Department of Clinical sciences at Lund University and consultant pediatrician at Kristianstad hospital, Sweden. Sponsor of the trial is Diamyd Medical. About DiaPrecise - precision Prevention of Type 1 Diabetes: Diamyd®?

is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Diamyd®?, a confirmatory Phase III trial is actively recruting patients with recent-onset Type 1 Diabetes in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company's European Phase IIb trial DIAGNODE-2, where Diamyd®?

was administered directly into a lymph node in a lymph node in the U.S. and Novo Nordisk as partners.